에 대한 최신 뉴스 Datadog (NASDAQ:DDOG) 주식

Datadog

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.

Equities

News

Markets

ETFs

$BTC

ARKF

ARKK

ARKQ

ARKW

ARKX

COIN

DDOG

DKNG

PLTR

RKLB

TWST

화요일에 캐시 우드가 이끄는 아크 인베스트는 몇 가지 중요한 거래를 했다. 그중 가장 눈에 띄는 것은 팔란티어 테크놀로지스(NYSE:PLTR)의 주식 매수와 코인베이스 글로벌(NASDAQ:COIN)의 주식 매각이었다.
팔란티어(PLTR) 거래:

아크 인베스트는 팔란티어 주식 $2,900만 상당 매수, $1,500만 이상의 코인베이스 주식 매각

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

PINS

PSNL

TWLO

VERV

수요일, Cathie Wood의 Ark Invest가 Pinterest Inc (NYSE:PINS)의 추가 주식을 구매하는 것으로 눈에 띄는 움직임을 보였다.



핀터레스트의 거래



Ark Invest의 Fintech Innovation ETF(NYSE:ARKF)는 인스타그램과 X 플랫폼을 소유한 메타 플랫폼의 경쟁사인 인기 있는 소셜 미디어 웹사이트인 Pinterest 26,925주의

캐시 우드의 아크 인베스트는 메타 플랫폼 경쟁사의 주식을 추가 매입

Datadog Inc

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Guidance

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

WIIM

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent. This is a 0.37 percent increase over sales of $511.65 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

BBAI

BigBear.ai Affirms 2024 Revenue Guidance $165M-$180M

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

GMED

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

In a report released today, Koji Ikeda from Bank of America Securities maintained a Buy rating on Datadog (DDOG – Research Report). The company's s...

New Buy Rating for Datadog (DDOG), the Technology Giant

Baron Technology Fund Q3 2024 Shareholder Letter

Palantir Q3 Preview: Path To $61 Is Possible

Andrew Sherman, an analyst from TD Cowen, maintained the Buy rating on Datadog (DDOG – Research Report). The associated price target was raised to ...

Strong Growth Prospects for Datadog Driven by Product Adoption, AI Advancements, and Strategic Positioning

Baron Fifth Avenue Growth Fund Q3 2024 Shareholder Letter

Baron Global Advantage Fund Q3 2024 Shareholder Letter

Datadog (DDOG – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Koji Ikeda from Bank of Amer...

Positive Growth Outlook for Datadog with Continued Buy Rating

Earnings week ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and more

Stifel Nicolaus analyst Brad Reback maintained a Buy rating on Datadog (DDOG – Research Report) today and set a price target of $135.00. The compan...

Datadog (DDOG): New Buy Recommendation for This Technology Giant

There's a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Trade Desk (TTD – Research Report), Microchip (MCHP ...

Analysts Are Bullish on Top Technology Stocks: Trade Desk (TTD), Microchip (MCHP)

AAPL

ABNB

ADYEY

ADYYF

AFRM

AMZN

ANET

ARGNF

ARGX

ASML

ASMLF

AVGO

AXON

BCAP

BESIY

BESVF

BLNK

BNTX

BROE

BSQKZ

BYND

CPNG

CRSP

CRWD

CTVA

DAVA

DUOL

FANG

GDHLF

GILD

GOOG

GOOGL

GTLB

GWRE

HUBS

ILMN

INDI

INTA

ISRG

LCID

LRCX

LUMN

LYFT

MAIN

MARA

MBLY

MCHP

MELI

MNDY

MRNA

MSFT

NVAX

NVDA

NXPI

OPEN

ORCL

PARA

QCOM

RDDT

RIVN

SEDG

SHOP

SNOW

SONY

SPCE

SPOT

SSNLF

TEAM

TEVA

TSLA

TSMWF

TTWO

UPST

VRTX

VTRS

WYNN

Press Releases

Datadog Welcomes David Galloreese as New Chief People Officer

Datadog Announces Date of Second Quarter Fiscal Year 2024 Earnings Call

Datadog Appoints Yanbing Li as Chief Product Officer

Datadog to Present at Upcoming Investor Conferences

Datadog Announces Second Quarter 2024 Financial Results

Datadog Named a Leader in the 2024 Gartner® Magic Quadrant™ For Observability Platforms

Datadog Announces the General Availability of Datadog Monitoring for Oracle Cloud Infrastructure

Datadog Announces Date of Third Quarter Fiscal Year 2024 Earnings Call

Datadog's State of Cloud Security 2024 Finds Room for Improvement in the Use of Long-Lived Credentials Across All Major Clouds

Datadog Named a Leader in the 2024 Gartner® Magic Quadrant™ For Digital Experience Monitoring

Comments

Datadog

뉴스

에 대한 최신 뉴스 Datadog (NASDAQ:DDOG) 주식

수요일, 5월 08, 2024

목요일, 4월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌